BOC Sciences Newly Launched Inhibitor Exatecan Mesylate for Anticancer Drug Research

November 21 18:16 2017

On November 21, 2017, the world leading chemical supplier BOC Sciences launched exatecan mesylate (CAS 169869-90-3), adding to its best-selling inhibitor categories. Due to its great anticancer potential, exatecan mesylate has been broadly tested in anticancer clinical trials. This move of BOC Sciences is expected to bring much convenience for researchers who are seeking for the inhibitor exatecan. 

Exatecan mesylate (or Exatecan), also referred to as DX-8951, is a type of topoisomerase inhibitor. “Exatecan is a semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. It can inhibit topoisomerase I activity,” reveals the Chief Scientist of the R&D team at BOC Sciences. He further expounds the underlying rationale, “By stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, exatecan mesylate can thereby inhibit DNA replication and trigger apoptotic cell death.”

Exatecan (CAS 171335-80-1) does not require enzymatic activation and exhibits greater tumour efficacy than camptothecin and other camptothecin analogues. Meanwhile, less toxicity is another major advantage that makes it unique among all its analogues.  

“Among all the relevant researches currently being conducted, exatecan mesylate is found to be effective in patients aged from 15 to 75 who have advanced soft tissue sarcoma,” says the Chief Scientist at BOC Sciences. “It’s effective to various sarcomas, just to name a few here: malignant fibrous histiocytoma, liposarcoma, rhabdomyosarcoma, synovial sarcoma, Ewing’s sarcoma, etc.”

In another study, effects of exatecan mesylate are further explored in treating children with relapsed or refractory rhabdomyosarcoma. Traditionally chemotherapy uses different ways to interfere tumor cells growth or kill them by stopping their division.

The recommended dose for exatecan as a weekly 24-h infusion on a 3-of-4 week schedule is 0.8 mg/m2 in minimally pretreated patients and 0.53 mg/m2 in patients who are heavily pretreated.

“Considering the therapeutic potential of exatecan mesylate for other diseases as well such as non-small cell lung cancer, BOC Sciences decides to offer this inhibitor in larger stock with affordable price and also more swift delivery. Now exatecan are available at BOC Sciences in two different size, 1 mg and 10 mg respectively,” according to the Chief Scientist.

About BOC Sciences

As a major player in supply of chemicals (inhibitors, APIs, metabolites, impurities, GMP products, etc.), BOC Sciences gradually takes a leadership position in providing a wide range of services to support the pharmaceutical industry through all stages of drug discovery, covering Custom Synthesis of chemicals in no stock, Isotope Labeling Service, Chiral Synthesis and Resolution, analytical services and alike. BOC Sciences makes all the strategy shifts out of commitment to better serve its customers and clients. 

Media Contact
Company Name: BOC Sciences
Contact Person: Linna Green
Email: Send Email
Phone: 1-631-619-7922
Address:45-16 Ramsey Road
City: Shirley
State: NEW YORK
Country: United States
Website: http://www.bocsci.com

  Categories: